Cheung K L
Division of Breast Surgery, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
Breast. 2007 Aug;16(4):327-43. doi: 10.1016/j.breast.2007.03.004. Epub 2007 May 14.
Endocrine therapy for breast cancer has been established in the adjuvant treatment for primary disease and in the treatment of advanced disease. The ER remains the best predictor of response although other factors exist and need to be identified. Pharmacological manipulation has been replacing ablative procedures. Tamoxifen used to be the most popular agent of choice and promising new agents include the pure anti-oestrogens and the third generation selective aromatase inhibitors. Ongoing and future studies will optimise treatment in established areas and will exploit its potential roles in preoperative use and chemoprevention.
内分泌疗法已用于乳腺癌的原发性疾病辅助治疗和晚期疾病治疗。雌激素受体（ER）仍然是反应的最佳预测指标，尽管还存在其他因素且有待确定。药物治疗已逐渐取代切除手术。他莫昔芬曾是最常用的药物，而有前景的新型药物包括纯抗雌激素药物和第三代选择性芳香化酶抑制剂。正在进行的和未来的研究将优化现有领域的治疗方法，并探索其在术前使用和化学预防方面的潜在作用。
